Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Results: Head-to-Head Comparisons of DMARDs
In the two trials comparing D-penicillamine and hydroxychloroquine, methotrexate (MTX) was not given to either treatment group. No statistically significant differences between groups were found in disease activity or inflammation. Health status was not reported.
Sulfasalazine and hydroxychloroquine were compared in patients who did not receive MTX. The DMARDs produced similar outcomes in disease activity and inflammation levels, but no statistical analysis was reported. Health status was not reported.
Leflunomide and methotrexate were compared, but no statistically significant differences in disease activity, health status, or inflammation levels were noted.
Etanercept and infliximab were compared in patients who could also receive MTX. No statistically significant differences in disease activity, health status, or inflammation levels were noted.
Keywords: anti-rheumatic | antirheumatic | biologic DMARD | D-penicillamine | disease-modifying | DMARDs | erythrocyte sedimentation rate | ESR | etanercept | health status | hydroxychloroquine | infliximab | JCA | JIA | JRA | juvenile rheumatoid arthritis | leflunomide | methotrexate | non-biologic DMARD | nonbiologic DMARD | oligoarticular | parent global assessment | pauciarticular | physician global assessment | polyarticular | radiographic progression | rheumatic | sulfasalazine | systemic onset | TNF-alpha blockers | juvenile idiopathic arthritis
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.